Caricamento pagina
glp-1_hero_MB

Markets

Integrated Solutions for GLP-1 and Peptides

Supporting the growth of GLP-1 and peptide therapies

The rapid growth of GLP-1 and peptide-based therapies is reshaping the pharmaceutical landscape, driven by increasing demand for treatments in diabetes, obesity, and other chronic conditions. As these biologic molecules move toward large-scale adoption, pharmaceutical companies need reliable partners able to support product development, industrialization, and commercial supply. Stevanato Group responds to this evolving market with integrated solutions for GLP-1 and peptides, combining primary packaging, drug delivery devices, assembly equipment, and analytical services to help pharma partners bring safe, scalable, and patient-centric therapies to market.

GLP-1 and peptide key challenges

For pharma companies aiming to satisfy the surging demand, the choice of delivery mechanism and delivery partner will have implications for supply chain capacity and resilience. Optimizing the route to market for a GLP-1 & Peptides device requires assessment and resolution of risk in areas including drug containment and device specification, as well as scaled-up production, assembly, fill and finish, and distribution.

Key factors to consider include:

  • GlobalSupplyChain

    Supply chain security
    Significant demand puts pressure on global supply chains, making reliable production and supply continuity essential.

  • 72_Flexibility

    RTU primary packaging availability
    Ready-to-Use primary packaging is critical to ensure clinical supplies and support commercial scale-up.

  • 70_Less Time to Market

    Risk mitigation from development to commercialization
    Early assessment of drug containers, device specifications, and process requirements helps reduce risk across the product lifecycle.

  • 348_Water_diluent

    Time to market
    Speed is a key variable to seize market opportunities in the rapidly growing GLP-1 and peptide therapy space.

  • 317_Dose indication

    Drug product wastage
    Minimizing drug product loss is essential, particularly for high-value biologic molecules.

  • 10_Personnel-1

    Patient preferences
    Pen injectors and autoinjectors - offering fixed or variable dosing and single or multiple injections - can address diverse patient preferences across geographies

integrated offering infographic GLP-1

Explore our solutions for GLP-1 and peptides

Stevanato Group supports GLP-1 and peptide production processes with a comprehensive offering across the pharma value chain. Explore our solutions for primary packaging, drug delivery devices, visual inspection, assembly technologies, and analytical services.

Our Solutions

analytical_services_preview

Analytical and Testing Services

preview_nexa_Syringes_Solutions

EZ-fill® Nexa® Syringes

preview_nexa_cartridges

EZ-fill® Nexa® Cartridges

aidaptus_preview

Aidaptus®

alina_preview

Alina®

deora_preview

Deora™

automatic_visual_inspection_preview

Visual Inspection Equipment

assembly_preview

Assembly & Packaging Equipment​

preview_ez-fill_kit

EZ-fill® Kit

Are you in a clinical phase? Discover how EZ-fill® Kit can help you.

Discover more

GLP-1 drug delivery and packaging solutions: media and resources

Alina_30_in_use_hero_article

White Paper: How RTU cartridges support GLP-1 packaging compatibility

The rapid growth of GLP-1-based therapies is reshaping the pharmaceutical landscape, driving unprecedented demand for reliable, scalable, and cost-effective delivery systems

white paper glp-1 drug delivery systems

White Paper: Simplifying GLP-1 delivery

Stevanato Group presents complete, integrated solution. Read the white paper.

SG_Alina

Article: Delivering on GLP-1 demand

A combination of device offerings and supply strategy. Read our article.